Free Trial

Travere Therapeutics (TVTX) Short Interest Ratio & Short Volume

Travere Therapeutics logo
$18.09 +0.30 (+1.67%)
As of 03:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Travere Therapeutics Short Interest Data

Travere Therapeutics (TVTX) has a short interest of 10.62 million shares, representing 12.44% of the float (the number of shares available for trading by the public). This marks a -17.42% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.8, indicating that it would take 6.8 days of the average trading volume of 1.64 million shares to cover all short positions.

Current Short Interest
10,620,000 shares
Previous Short Interest
12,860,000 shares
Change Vs. Previous Month
-17.42%
Dollar Volume Sold Short
$164.08 million
Short Interest Ratio
6.8 Days to Cover
Last Record Date
July 31, 2025
Outstanding Shares
89,140,000 shares
Short Percent of Float
12.44%
Today's Trading Volume
898,040 shares
Average Trading Volume
1,643,325 shares
Today's Volume Vs. Average
55%
Short Selling Travere Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Travere Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

TVTX Short Interest Over Time

TVTX Days to Cover Over Time

TVTX Percentage of Float Shorted Over Time

Travere Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/31/202510,620,000 shares $164.08 million -17.4%12.4%6.8 $15.45
7/15/202512,860,000 shares $210.65 million +857,233.3%N/A7.9 $16.38
6/30/20251,500 shares $22.20 thousand -100.0%0.0%0 $14.80
6/15/202510,330,000 shares $149.79 million -17.4%12.1%5.9 $14.50
5/31/202512,500,000 shares $187.25 million +19.9%16.6%7.1 $14.98
5/15/202510,430,000 shares $220.59 million -2.0%13.9%5.8 $21.15
4/30/202510,640,000 shares $221.42 million -3.7%N/A5.7 $20.81
4/15/202511,050,000 shares $164.76 million -4.4%14.7%6.2 $14.91
3/31/202511,560,000 shares $207.16 million +3.3%15.4%6.6 $17.92
3/15/202511,190,000 shares $220.78 million +2.2%14.9%7 $19.73
2/28/202510,950,000 shares $234.33 million -3.1%14.6%7.2 $21.40
2/15/202511,300,000 shares $258.88 million +18.2%15.0%7.7 $22.91
1/31/20259,560,000 shares $195.60 million -0.2%N/A6.8 $20.46
1/15/20259,580,000 shares $173.11 million +9.9%N/A7.4 $18.07
12/31/20248,720,000 shares $151.90 million +17.7%N/A5.9 $17.42
12/15/20247,410,000 shares $128.34 million -2.1%N/A4.5 $17.32
11/30/20247,570,000 shares $142.39 million +8.6%N/A4.3 $18.81
11/15/20246,970,000 shares $123.51 million -12.8%N/A3.6 $17.72
10/31/20247,990,000 shares $139.83 million -1.5%N/A4.4 $17.50
10/15/20248,110,000 shares $143.47 million +16.5%N/A4.7 $17.69
9/30/20246,960,000 shares $97.37 million -19.6%N/A4.2 $13.99
9/15/20248,660,000 shares $116.74 million -6.4%N/A6.2 $13.48
8/31/20249,250,000 shares $87.60 million -0.5%N/A7.2 $9.47
8/15/20249,300,000 shares $81.65 million -7.8%N/A8.5 $8.78
7/31/202410,090,000 shares $96.26 million -0.1%N/A8.8 $9.54
7/15/202410,100,000 shares $99.08 million -2.1%N/A8.2 $9.81
6/30/202410,320,000 shares $84.83 million -23.1%N/A8.2 $8.22
6/15/202413,414,700 shares $96.18 million -0.4%N/A11 $7.17
5/31/202413,470,000 shares $99.95 million +0.2%N/A11.3 $7.42
5/15/202413,440,000 shares $91.39 million +4.9%N/A11 $6.80
4/30/202412,810,000 shares $70.84 million +8.6%N/A10.3 $5.53
4/15/202411,800,000 shares $74.58 million +11.3%N/A9.9 $6.32
3/31/202410,600,000 shares $81.73 million +5.3%N/A8.8 $7.71
3/15/202410,070,000 shares $75.42 million -1.9%N/A8.2 $7.49
2/29/202410,260,000 shares $77.57 million +5.1%N/A7.5 $7.56
2/15/20249,760,000 shares $85.30 million -1.7%N/A6.7 $8.74
1/31/20249,930,000 shares $88.67 million +2.3%N/A6.3 $8.93
1/15/20249,710,000 shares $92.54 million -2.1%N/A5.8 $9.53
12/31/20239,920,000 shares $89.18 million +2.9%N/A5.9 $8.99
12/15/20239,640,000 shares $83.48 million -3.1%N/A5.8 $8.66
Trump’s national nightmare is here (Ad)

Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel

Watch the National Emergency broadcast here
11/30/20239,950,000 shares $62.49 million -6.7%N/A5 $6.28
11/15/202310,660,000 shares $65.77 million +21.0%N/A5.9 $6.17
10/31/20238,810,000 shares $57.09 million +0.5%N/A5.2 $6.48
10/15/20238,770,000 shares $62.27 million +4.2%N/A5.6 $7.10
9/30/20238,420,000 shares $75.27 million -6.9%N/A5.8 $8.94
9/15/20239,040,000 shares $123.76 million +5.7%N/A6.7 $13.69
8/31/20238,550,000 shares $122.09 million +5.6%N/A8.3 $14.28
8/15/20238,100,000 shares $123.12 million +0.4%N/A7.6 $15.20
7/31/20238,070,000 shares $138.72 million -2.7%N/A7.3 $17.19
7/15/20238,290,000 shares $126.92 million -2.5%N/A6.5 $15.31
6/30/20238,500,000 shares $130.56 million +11.0%N/A6.3 $15.36
6/15/20237,660,000 shares $131.75 million +4.9%N/A5.4 $17.20
5/31/20237,300,000 shares $130.60 million -3.2%N/A5.4 $17.89
5/15/20237,540,000 shares $123.20 million -4.1%N/A4.7 $16.34
4/30/20237,860,000 shares $169.54 million -3.7%N/A4.7 $21.57
4/15/20238,160,000 shares $165.81 million -4.5%N/A5.6 $20.32
3/31/20238,540,000 shares $192.06 million +14.8%N/A5.7 $22.49
3/15/20237,440,000 shares $158.25 million -1.6%N/A5.4 $21.27
2/28/20237,560,000 shares $167.53 million +9.9%N/A5.7 $22.16
2/15/20236,880,000 shares $138.43 million -7.7%N/A5.8 $20.12
1/31/20237,450,000 shares $166.88 million -0.9%N/A8.8 $22.40
1/15/20237,520,000 shares $152.81 million -10.3%N/A9.1 $20.32
12/30/20228,380,000 shares $176.23 million +3.1%N/A10 $21.03
12/15/20228,130,000 shares $150.41 million -1.2%N/A9.7 $18.50
11/30/20228,230,000 shares $165.67 million +5.9%N/A10.6 $20.13
11/15/20227,770,000 shares $167.13 million -1.2%N/A10.4 $21.51
10/31/20227,860,000 shares $170.40 million +23.0%13.0%10.9 $21.68
10/15/20226,390,000 shares $132.15 million -6.2%10.6%8.4 $20.68
9/30/20226,810,000 shares $167.80 million +3.0%11.3%10.3 $24.64
9/15/20226,610,000 shares $179.79 million -0.5%11.0%9.9 $27.20
8/31/20226,640,000 shares $177.69 million -10.2%11.1%9 $26.76
8/15/20227,390,000 shares $211.28 million +7.9%12.3%9.7 $28.59
7/31/20226,850,000 shares $161.25 million +2.4%11.5%7.9 $23.54
7/15/20226,690,000 shares $163.97 million -5.0%11.2%8.4 $24.51
6/30/20227,040,000 shares $170.58 million +6.2%11.8%8.6 $24.23
6/15/20226,630,000 shares $160.18 million -10.4%11.1%8 $24.16
5/31/20227,400,000 shares $172.49 million -12.6%12.4%8.9 $23.31
5/15/20228,470,000 shares $187.86 million +3.7%14.2%9.7 $22.18
4/30/20228,170,000 shares $205.31 million +14.1%13.8%10.5 $25.13
4/15/20227,160,000 shares $212.22 million +0.7%12.1%9.3 $29.64
3/31/20227,110,000 shares $183.22 million -6.5%12.0%9.8 $25.77
3/15/20227,600,000 shares $181.72 million +29.3%12.8%11.5 $23.91
2/28/20225,880,000 shares $160.29 million -1.7%10.0%9.1 $27.26
2/15/20225,980,000 shares $171.39 million +11.4%10.5%11 $28.66
1/31/20225,370,000 shares $147.68 million +8.5%9.3%10.6 $27.50
1/15/20224,950,000 shares $136.32 million -15.5%8.5%9.3 $27.54
12/31/20215,860,000 shares $181.89 million -6.4%N/A0 $31.04
12/15/20216,260,000 shares $182.48 million +0.6%10.8%11.6 $29.15
11/30/20216,220,000 shares $177.58 million +3.0%10.7%10.5 $28.55
11/15/20216,040,000 shares $177.39 million -1.2%10.4%9.7 $29.37
Trump’s national nightmare is here (Ad)

Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel

Watch the National Emergency broadcast here
10/29/20216,110,000 shares $176.03 million +0.5%10.1%5 $28.81
10/15/20216,080,000 shares $148.96 million -6.9%10.2%5.1 $24.50
9/30/20216,530,000 shares $158.35 million -5.6%10.9%5.4 $24.25
9/15/20216,920,000 shares $162.83 million -3.1%11.5%5.4 $23.53
8/31/20217,140,000 shares $155.87 million +6.7%11.9%5.5 $21.83
8/13/20216,690,000 shares $103.36 million -1.6%11.2%4.9 $15.45
7/30/20216,800,000 shares $93.50 million +2.6%11.4%8.3 $13.75
7/15/20216,630,000 shares $90.83 million -1.5%11.1%8 $13.70
6/30/20216,730,000 shares $98.19 million +23.0%11.3%8.3 $14.59
6/15/20215,470,000 shares $81.67 million +19.4%9.2%7.5 $14.93
5/28/20214,580,000 shares $69.48 million -0.4%7.7%7 $15.17
5/14/20214,600,000 shares $86.94 million -3.2%7.7%8.7 $18.90
4/30/20214,750,000 shares $117.85 million -1.5%8.0%8.2 $24.81
4/15/20214,820,000 shares $122.48 million -6.4%8.1%7.7 $25.41
3/31/20215,150,000 shares $125.25 million +20.9%8.6%8.3 $24.32
3/15/20214,260,000 shares $122.43 million +3.2%7.2%6.9 $28.74
2/26/20214,130,000 shares $122.66 million -1.7%7.0%6.9 $29.70
2/12/20214,200,000 shares $116.72 million -0.7%7.4%7.3 $27.79
1/29/20214,230,000 shares $109.09 million -2.8%8.4%8.9 $25.79
1/15/20214,350,000 shares $126.67 million No Change8.6%11.1 $29.12

TVTX Short Interest - Frequently Asked Questions

What is Travere Therapeutics' current short interest?

Short interest is the volume of Travere Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 10,620,000 shares of TVTX short. 12.44% of Travere Therapeutics' shares are currently sold short. Learn More on Travere Therapeutics' current short interest.

What is a good short interest ratio for Travere Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TVTX shares currently have a short interest ratio of 7.0. Learn More on Travere Therapeutics's short interest ratio.

Which institutional investors are shorting Travere Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Travere Therapeutics: Group One Trading LLC, Caption Management LLC, JPMorgan Chase & Co., and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Travere Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.44% of Travere Therapeutics' floating shares are currently sold short.

Is Travere Therapeutics' short interest increasing or decreasing?

Travere Therapeutics saw a decrease in short interest in July. As of July 31st, there was short interest totaling 10,620,000 shares, a decrease of 17.4% from the previous total of 12,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Travere Therapeutics' short interest compare to its competitors?

12.44% of Travere Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Travere Therapeutics: Rhythm Pharmaceuticals, Inc. (7.23%), Avidity Biosciences, Inc. (13.10%), Nuvalent, Inc. (11.99%), Axsome Therapeutics, Inc. (9.47%), CRISPR Therapeutics AG (26.94%), Abivax SA Sponsored ADR (2.78%), Merus N.V. (6.44%), Cytokinetics, Incorporated (13.26%), Viking Therapeutics, Inc. (26.61%), TG Therapeutics, Inc. (16.53%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

What does it mean to sell short Travere Therapeutics stock?

Short selling TVTX is an investing strategy that aims to generate trading profit from Travere Therapeutics as its price is falling. TVTX shares are trading up $0.32 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Travere Therapeutics?

A short squeeze for Travere Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TVTX, which in turn drives the price of the stock up even further.

How often is Travere Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TVTX, twice per month. The most recent reporting period available is July, 31 2025.




This page (NASDAQ:TVTX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners